|Expense Ratio (net)||0.74%|
|Morningstar Risk Rating||★★★★★|
|Last Cap Gain||0.00|
|Inception Date||Dec 16, 1985|
|Average for Category||N/A|
Removal of healthcare restrictions and biotech gains make mutual funds from this sector a strong investment choice.
Fidelity Select Biotechnology Portfolio (FBIOX) seeks capital appreciation
Invest in Fidelity mutual funds in April after winning multiple fund awards.